Class a capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation.
Fiche publication
Date publication
avril 2023
Journal
Hepatology (Baltimore, Md.)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BAUMERT Thomas, Dr VERRIER Eloi
Tous les auteurs :
Kum DB, Vanrusselt H, Acosta Sanchez A, Taverniti V, Verrier ER, Baumert TF, Liu C, Deval J, Corthout N, Munck S, Beigelman L, Blatt LM, Symons JA, Raboisson P, Jekle A, Vendeville S, Debing Y
Lien Pubmed
Résumé
Effective therapies leading to a functional cure of chronic hepatitis B (CHB) are still lacking. Class A capsid assembly modulators (CAM-As) are an attractive modality to address this unmet medical need. CAM-As induce aggregation of the HBV core protein (HBc) and lead to sustained HBsAg reductions in a CHB mouse model. Here we investigate the underlying mechanism of action for CAM-A compound RG7907.
Référence
Hepatology. 2023 04 28;: